developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer
Company profile
Ticker
ZNTL
Exchange
Website
CEO
Kimberly Lynn Blackwell
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Zeno Pharma, LLC, Zentalis Pharmaceuticals, LLC
SEC CIK
Corporate docs
Subsidiaries
Zeno Management, Inc. • Zeno Pharmaceuticals, Inc. • Zeno Alpha, Inc. • K-Group Alpha, Inc. • K-Group Beta, Inc. • Zentalis Pharmaceuticals Australia Pty Ltd. ...
ZNTL stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
29 Feb 24
S-3ASR
Automatic shelf registration
29 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
27 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
15 Feb 24
8-K
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
25 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
6 Nov 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
Latest ownership filings
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Avidity Partners Management LP
13 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
144
Notice of proposed sale of securities
12 Feb 24
144
Notice of proposed sale of securities
12 Feb 24
144
Notice of proposed sale of securities
12 Feb 24
4
Melissa B, Epperly
12 Feb 24
4
Cam Gallagher
12 Feb 24
SC 13G/A
Capital International Investors
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 113.38 mm | 113.38 mm | 113.38 mm | 113.38 mm | 113.38 mm | 113.38 mm |
Cash burn (monthly) | 51.94 mm | (no burn) | 20.91 mm | 24.70 mm | 12.89 mm | 17.05 mm |
Cash used (since last report) | 309.30 mm | n/a | 124.51 mm | 147.10 mm | 76.76 mm | 101.52 mm |
Cash remaining | -195.92 mm | n/a | -11.13 mm | -33.72 mm | 36.62 mm | 11.86 mm |
Runway (months of cash) | -3.8 | n/a | -0.5 | -1.4 | 2.8 | 0.7 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 134 |
Opened positions | 15 |
Closed positions | 14 |
Increased positions | 52 |
Reduced positions | 38 |
13F shares | Current |
---|---|
Total value | 1.60 tn |
Total shares | 80.02 mm |
Total puts | 39.70 k |
Total calls | 199.60 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Matrix Capital Management | 13.96 mm | $280.04 bn |
FMR | 9.49 mm | $190.45 bn |
Eventide Asset Managment | 7.81 mm | $156.75 bn |
Vanguard | 5.24 mm | $105.05 bn |
BLK Blackrock | 4.40 mm | $88.18 bn |
Capital International Investors | 3.13 mm | $62.74 bn |
T. Rowe Price | 2.72 mm | $54.47 bn |
STT State Street | 2.70 mm | $54.23 bn |
Citadel Advisors | 2.16 mm | $43.24 bn |
Avidity Partners Management | 2.10 mm | $42.13 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Feb 24 | Melissa B, Epperly | Common Stock | Sell | Dispose S | No | Yes | 11.44 | 2,573 | 29.44 k | 451,449 |
12 Feb 24 | Cam Gallagher | Common Stock | Sell | Dispose S | No | Yes | 11.44 | 1,173 | 13.42 k | 643,277 |
2 Feb 24 | Melissa B, Epperly | Common Stock | Sell | Dispose S | No | Yes | 11.54 | 8,669 | 100.04 k | 454,022 |
2 Feb 24 | Cam Gallagher | Common Stock | Sell | Dispose S | No | Yes | 11.54 | 11,552 | 133.31 k | 644,450 |
1 Feb 24 | Kimberly Blackwell | Common Stock | Payment of exercise | Dispose F | No | No | 11.69 | 20,655 | 241.46 k | 484,145 |
1 Feb 24 | Kimberly Blackwell | Common Stock | Grant | Acquire A | No | No | 0 | 250,000 | 0.00 | 504,800 |
1 Feb 24 | Kimberly Blackwell | Stock Option Common Stock | Grant | Acquire A | No | No | 11.69 | 250,000 | 2.92 mm | 250,000 |
1 Feb 24 | Melissa B, Epperly | Common Stock | Grant | Acquire A | No | No | 0 | 75,000 | 0.00 | 462,691 |
1 Feb 24 | Melissa B, Epperly | Stock Option Common Stock | Grant | Acquire A | No | No | 11.69 | 75,000 | 876.75 k | 75,000 |
1 Feb 24 | Cam Gallagher | Common Stock | Grant | Acquire A | No | No | 0 | 192,500 | 0.00 | 656,002 |
News
HC Wainwright & Co. Reiterates Buy on Zentalis Pharma, Maintains $46 Price Target
28 Feb 24
Wedbush Maintains Neutral on Zentalis Pharma, Raises Price Target to $15
28 Feb 24
Zentalis Pharma FY EPS $(4.47) Up From $(4.48) YoY; Cash Balance Of $483M, With Projected Cash Runway Into 2026
27 Feb 24
Immunome, Zentalis Enter Exclusive, Worldwide License Agreement; Zentalis To Receive Up-front Payment Of $35M & Up To $275M Of Milestone Payments
8 Jan 24
Press releases
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 Mar 24
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
27 Feb 24
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 Feb 24
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
25 Jan 24
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
8 Jan 24